about
Management of intracerebral hemorrhage--use of statinsEvaluation of diagnostic tests and argatroban or lepirudin therapy in patients with suspected heparin-induced thrombocytopenia.Evaluation of bivalirudin treatment for heparin-induced thrombocytopenia in critically ill patients with hepatic and/or renal dysfunction.Safety, efficacy, and dosing requirements of bivalirudin in patients with heparin-induced thrombocytopenia.Prefilter bivalirudin for preventing hemofilter occlusion in continuous renal replacement therapy.Evaluation of empiric versus nomogram-based direct thrombin inhibitor management in patients with suspected heparin-induced thrombocytopenia.Antithrombotic therapy in patients with thrombocytopenic cancer: outcomes associated with reduced-dose, low-molecular-weight heparin during hospitalization.Cerebral Vasospasm in Critically III Patients with Aneurysmal Subarachnoid Hemorrhage: Does the Evidence Support the Ever-Growing List of Potential Pharmacotherapy Interventions?Levofloxacin pharmacokinetics and pharmacodynamics in patients with severe burn injury.Evaluation of sulfobutylether-β-cyclodextrin (SBECD) accumulation and voriconazole pharmacokinetics in critically ill patients undergoing continuous renal replacement therapyEvaluation of Sulfobutylether-β-Cyclodextrin Exposure in a Critically Ill Patient Receiving Intravenous Posaconazole While Undergoing Continuous Venovenous HemofiltrationTreatment of hepatorenal syndrome.Systemic anticoagulation considerations in chronic kidney disease.Management of extravasation injuries: a focused evaluation of noncytotoxic medications.Proton pump inhibitors and histamine-2 receptor antagonists in the intensive care setting: focus on therapeutic and adverse events.Severe acute exacerbations of chronic obstructive pulmonary disease: does the dosage of corticosteroids and type of antibiotic matter?Research fellowship programs as a pathway for training independent clinical pharmacy scientists.Adjunctive dexmedetomidine therapy in the intensive care unit: a retrospective assessment of impact on sedative and analgesic requirements, levels of sedation and analgesia, and ventilatory and hemodynamic parameters.Evaluation of phenylephrine stability in polyvinyl chloride bags.A survey of prescriber perceptions about the prevention of stress-related mucosal bleeding in the intensive care unit.Correlation of pharmacokinetic/pharmacodynamic-derived predictions of antibiotic efficacy with clinical outcomes in severely ill patients with Pseudomonas aeruginosa pneumonia.Bivalirudin versus unfractionated heparin for prevention of hemofilter occlusion during continuous renal replacement therapy.Efflux pump contribution to multidrug resistance in clinical isolates of Pseudomonas aeruginosa.Propylene glycol accumulation in critically ill patients receiving continuous intravenous lorazepam infusions.Evaluation of valganciclovir pharmacokinetics in lung transplant recipients.Outcomes associated with corticosteroid dosage in critically ill patients with acute exacerbations of chronic obstructive pulmonary disease.Reliability and accuracy of practitioner-calculated Acute Physiology and Chronic Health Evaluation II scores for determining the appropriateness of drotrecogin alfa (activated).Erythromycin vs metoclopramide for facilitating gastric emptying and tolerance to intragastric nutrition in critically ill patients.Vasopressin, not octreotide, may be beneficial in the treatment of hepatorenal syndrome: a retrospective study.Gastric motility function in critically ill patients tolerant vs intolerant to gastric nutrition.Weight-based versus set dosing of vancomycin for coronary artery bypass grafting or aortic valve surgery.A randomized, double-blind, placebo-controlled dose range study of dexmedetomidine as adjunctive therapy for alcohol withdrawal.Stability of phenylephrine hydrochloride injection in polypropylene syringes.Stability of acetylcysteine solution repackaged in oral syringes and associated cost savings.Key articles and guidelines in the management of pulmonary arterial hypertension: 2011 update.Continuous infusion vs intermittent vancomycin in neurosurgical intensive care unit patients.Reporting Guidelines for Clinical Pharmacokinetic Studies: The ClinPK StatementEvaluation of unfractionated heparin versus low-molecular-weight heparin and fondaparinux for pharmacologic venous thromboembolic prophylaxis in critically ill patients with cancerComparative evaluation of isavuconazonium sulfate, voriconazole, and posaconazole for the management of invasive fungal infections in an academic medical centerNeuromuscular blockade resistance during therapeutic hypothermia
P50
Q26752952-0A936654-6157-4999-88B7-F3B83EB52825Q33369330-FB69190B-AD4F-436A-9874-76D5A51AC52EQ33370636-0651101A-597B-4F7A-975A-1C5190792622Q33380931-A29C247F-7972-442E-9BE4-DC4396391CDFQ33385297-9C4B9A44-2552-4CAA-A2E8-87CAFE37AD9CQ33394199-C9515B0C-45E8-4781-A653-1A06A55E8C20Q33416407-F4162217-6E3D-4CD9-B6CD-430114A0D912Q34612924-42DFBED1-8F96-49C3-8448-0F0364475251Q34680572-70F19D03-BB09-4293-B99A-6D0E6FDB24ADQ35114591-C235890A-DB4D-4DC3-B2A1-73224C70A0DBQ36076106-4AD9A911-F158-4032-B5A8-785F1F1DB650Q37605883-AFAA9C52-168B-43FD-BCF6-77E53AFA7FF4Q37781454-18269006-126D-47C6-B4B3-BFC3159344A8Q38178196-9A73BEFD-EFF3-4EFC-B96A-99D8E5CD7D2FQ38271282-EBF1C8FC-25B9-4754-9B26-8BDE5BA3C410Q38313064-122E195E-2599-47F7-8ED5-0FC836379FA1Q38371982-08A94F91-A011-427F-AA06-71F628EACCD3Q40240359-75A25F5B-DC12-4739-9C87-164918EF63F8Q40864630-46968463-9360-4217-B500-44B31989FC97Q41730777-2AD99EE1-425D-41CC-8AE6-13C3CEA7CF97Q42259839-EB325807-750D-41C6-816B-6114C3BB23D1Q42848627-A65A8DAF-1FF1-467B-AE12-3566A9E70BADQ43006550-BA0C4425-6463-4E9F-BE6C-198950C1E54CQ43240250-5D19B223-551E-4740-9380-DA5D85C53A08Q43689553-F72C69FA-8774-4346-8A61-7221F746D476Q45015016-164189DD-AF95-499C-9371-C00579874759Q45891249-C7B85F3B-AEC2-49E1-BC1E-5CF5DC9F220FQ46506002-C818ABEE-7D09-442F-B8F1-ADD25231138FQ46546915-FC389BEE-CA5F-4168-A657-1DC5A2348C9EQ46828380-0DEF13AB-18B5-4087-9071-465A51616D28Q47183622-BEB11E18-48B2-4FEE-83A9-E905AB5EC056Q50743455-B0731962-ED72-4F0E-80D2-AC4A0989E18CQ51007243-85F000FE-63A0-4505-AABE-C5505B139307Q51039234-AC8E0D58-3527-4EBF-B76D-5A67359885FCQ51613389-8B063C58-BC73-4A3D-A727-B5B36D7A7F27Q53396520-58929F13-B17E-4399-A329-603EF4FA3E4FQ56880220-772D6E45-C332-4AF8-B5BF-CA003F4B9F08Q57804230-DFC2B9B7-AECA-4E3D-AF6F-AD518A6A30BFQ64068520-D6D41FB8-FD64-43BA-92E1-D2E912794743Q83565159-0C453AA0-F3C7-4490-8798-7B1997733380
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Tyree H. Kiser
@ast
Tyree H. Kiser
@en
Tyree H. Kiser
@es
Tyree H. Kiser
@nl
Tyree H. Kiser
@sl
type
label
Tyree H. Kiser
@ast
Tyree H. Kiser
@en
Tyree H. Kiser
@es
Tyree H. Kiser
@nl
Tyree H. Kiser
@sl
altLabel
Ty Kiser
@en
prefLabel
Tyree H. Kiser
@ast
Tyree H. Kiser
@en
Tyree H. Kiser
@es
Tyree H. Kiser
@nl
Tyree H. Kiser
@sl
P106
P1153
9942848500
P31
P496
0000-0001-7415-3999